Foghorn Therapeutics Inc — Quarterly Financial Statistics (NASDAQ:FHTX) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Cash from operating activities 21 M24.52 M23.97 M21 M18.86 M 88.35 M Cash from investing activities 43.08 M-22.29 M29.4 M33.83 M35.57 M 76.52 M Cash from financing activities 1.05 M4 000139 K254 K49 K 446 K Free cash flow 20.7 M24.04 M23.94 M20.98 M18.86 M 87.82 M

News

Foghorn Therapeutics names Ryan Maynard as chief financial officer

Jefferies initiates Foghorn Therapeutics stock with buy rating

Top Healthcare Stocks for This Year According to BTIG

Foghorn Therapeutics stock reaffirmed as Buy by BTIG, named top pick for 1H26

Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 target

3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment

BTIG initiates Foghorn Therapeutics stock with Buy rating on cancer pipeline

Foghorn Therapeutics appoints Jeff Sacher as interim CFO and treasurer

Stifel initiates Foghorn Therapeutics stock with Buy rating, $12 target

Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 133.27% as Wall Street Analysts Expect?

4D Molecular Therapeutics appoints Kristian Humer as chief financial officer

This Aardvark Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday - Foghorn Therapeutics (NASDAQ:FHTX), Aardvark Therapeutics (NASDAQ:AARD)